ライフサイエンスコーパス: neurocognitive disorder

1 es, which are dysregulated in HIV-associated neurocognitive disorder.

2 cannot be better explained by a pre-existing neurocognitive disorder.

3 t in this population, such as HIV-associated neurocognitive disorder.

4 HIV-1 pathogenesis including HIV-associated neurocognitive disorder.

5 n of neurological function in HIV-associated neurocognitive disorders.

6 nosis and assessment of neuropsychiatric and neurocognitive disorders.

7 nodeficiency Virus type 1 (HIV-1)-associated neurocognitive disorders.

8 omenon that could lead to the development of neurocognitive disorders.

9 ndromes collectively known as HIV-associated neurocognitive disorders.

10 py of Alzheimer's disease and possibly other neurocognitive disorders.

11 ial therapeutic targets for HIV-1-associated neurocognitive disorders.

12 l as in the pathogenesis of HIV-1-associated neurocognitive disorders.

13 roved design of therapies for HIV-associated neurocognitive disorders.

14 reatment can be developed for HIV-associated neurocognitive disorders.

15 tribute to the development of HIV-associated neurocognitive disorders.

16 an effect has been found for HIV-associated neurocognitive disorders.

17 iates a process that causes HIV-1-associated neurocognitive disorders.

18 al nervous system HIV infection and clinical neurocognitive disorders.

19 ng cardiovascular disease, liver disease, or neurocognitive disorders.

20 -affected individuals, and the potential for neurocognitive disorders.

21 n regions have been implicated in a range of neurocognitive disorders.

22 ons such as delirium and other perioperative neurocognitive disorders.

23 en socioeconomic inequalities and subsequent neurocognitive disorders.

24 naptic transmission proteins associated with neurocognitive disorders.

25 al-task system has a high ability to predict neurocognitive disorders.

26 ving with HIV-1 suffer from mild to moderate neurocognitive disorders.

27 ne dysfunction underlies various cancers and neurocognitive disorders.

28 ions which could be the earliest red flag of neurocognitive disorders.

29 therapeutic strategy against HIV-associated neurocognitive disorders.

30 receptor (mAChR) is a biological target for neurocognitive disorders.

31 given that surgery has been associated with neurocognitive disorders.

32 dache, motor disturbances, seizures and even neurocognitive disorders.

33 roles of cAMP and beta-arrestin pathways in neurocognitive disorders.

34 treatment monitoring of neuropsychiatric and neurocognitive disorders.

35 icity and its deficiency was associated with neurocognitive disorders.

36 ed as a mediating factor of HIV-1 associated neurocognitive disorders.

37 current copy number variants associated with neurocognitive disorders.

38 promising novel targets for the treatment of neurocognitive disorders.

39 esents a novel target against HIV-associated neurocognitive disorders.

40 adaptive immune responses to HIV-associated neurocognitive disorders.

41 ators of neurodegeneration in HIV-associated neurocognitive disorders.

42 may offer protection against HIV-associated neurocognitive disorders.

43 ed as a risk determinant of HIV-1-associated neurocognitive disorders.

44 with HIV, and may exacerbate HIV-associated neurocognitive disorders.

45 ls, approximately 60% develop HIV-associated neurocognitive disorders.

46 the brain early in infection and can lead to neurocognitive disorders.

47 nefit for a CNS-T strategy in HIV-associated neurocognitive disorders.

48 nd oxidative stress has been associated with neurocognitive disorders.

49 role in the pathogenesis of HIV-1-associated neurocognitive disorders.

50 s 30.7% (HIV-associated dementia, 3.2%; mild neurocognitive disorder, 12.6%; and asymptomatic neuroco

51 ocognitive disorder, 12.6%; and asymptomatic neurocognitive disorder, 15.0%; HIV- group: 13.9%; P = .

52 95% CI, 12.4%-16.4%]), neurodevelopmental or neurocognitive disorders (5.7% [95% CI, 4.8%-6.5%] to 13

53 will promote consistency in the diagnosis of neurocognitive disorders across European countries.

54 e combination antiretroviral therapy (cART), neurocognitive disorders afflict 30-50% of HIV-infected

55 inhibitors confirmed the diagnosis of major neurocognitive disorders; all use of cholinesterase inhi

56 as used to investigate whether patients with neurocognitive disorder and behavioral disturbance (bvNC

57 sorders to include complex diseases, such as neurocognitive disorders and cancer predisposition.

58 lly deregulated in human diseases, including neurocognitive disorders and cancers.

59 injury is thought to underlie HIV-associated neurocognitive disorders and contributes to exaggerated

60 ts output values is limited to screening for neurocognitive disorders and does not extend to estimati

61 Despite the possible overlap between neurocognitive disorders and glaucoma in older individua

62 buting to neurological complications such as neurocognitive disorders and pain.

63 e to adjunctive treatment for HIV-associated neurocognitive disorders and/or prevent viral rebound in

64 s indicated a possible association with mild neurocognitive disorder, and a score higher than 27 poin

65 lenging disorders as delirium, perioperative neurocognitive disorder, and the sustained cognitive def

66 nst latent HIV-1 infection, HIV-1 associated neurocognitive disorders, and other HIV-1 comorbidities.

67 alth of offspring in later life, among which neurocognitive disorders are among the best described.

68 IMPORTANCE Neurocognitive disorders are frequently reported in peop

69 The utility of mild neurocognitive disorder as a distinct diagnostic categor

70 d had a higher prevalence of CVS plus (CVS + neurocognitive disorders) as compared to adult-onset CVS

71 cular disease, certain types of cancers, and neurocognitive disorders, as well as leaving them expose

72 icating the Toll-like receptors (TLR) in the neurocognitive disorders associated with NeuroAIDS in th

73 EPA, have shown effects in treating mood and neurocognitive disorders by reducing pro-inflammatory cy

74 nflammatory diseases, such as HIV-associated neurocognitive disorders, cancer, and atherosclerosis.

75 ave shown that HIV-infected patients develop neurocognitive disorders characterized by neuronal dysfu

76 ainst the progression to the early stages of neurocognitive disorders (CIND) and facilitate the poten

77 DSM-5 neurocognitive disorder criteria can be used reliably in

78 ilst the inter-rater reliability of the mild neurocognitive disorder criteria was modest, it does app

79 vestigate TBI-related pathology in new-onset neurocognitive disorders, depression, and posttraumatic

80 ral HIV DNA reservoir in the pathogenesis of neurocognitive disorder during suppressive ART.

81 Patients with neurocognitive disorders exhibited delirium (P < .001) a

82 h accuracy for differentiating patients with neurocognitive disorders from healthy controls.

83 When compared to the no neurocognitive disorder group, average neurofilament lig

84 ntal date were eligible for inclusion in the neurocognitive disorders group.

85 We enrolled 97 participants in the neurocognitive disorders group: 42 with Alzheimer's dise

86 tions were higher in both the mild and major neurocognitive disorder groups.

87 nflammation and symptoms of HIV-1-associated neurocognitive disorder (HAND) - a significant unmet cha

88 HIV-associated neurocognitive disorder (HAND) affects approximately hal

89 s role in immune response and HIV-associated neurocognitive disorder (HAND) has been widely studied.

90 HIV-associated neurocognitive disorder (HAND) is a common condition in

91 HIV-1 associated neurocognitive disorder (HAND) is characterized by neuro

92 een HIV-1 RNA discordance and HIV-associated neurocognitive disorder (HAND) may reflect compartmental

93 of HIV+ individuals; however, HIV-associated neurocognitive disorder (HAND) occurrence is increasing

94 tes with cognitive decline in HIV-associated neurocognitive disorder (HAND) patients.

95 Milder forms of HIV-associated neurocognitive disorder (HAND) remain common in HIV-infe

96 uman immunodeficiency virus (HIV)-associated neurocognitive disorder (HAND) remain unanswered.

97 nodeficiency virus type-1 (HIV-1)-associated neurocognitive disorder (HAND) remains an important neur

98 long with its contribution to HIV-associated neurocognitive disorder (HAND) remains ill-defined.

99 mpairment (GDS >/= 0.50), and HIV-associated neurocognitive disorder (HAND) using international crite

100 ins of individuals exhibiting HIV-associated neurocognitive disorder (HAND), likely driven by neuroin

101 tribute to the development of HIV-associated neurocognitive disorder (HAND), the prevalence of which

102 odegenerative syndrome termed HIV-associated neurocognitive disorder (HAND).

103 creases the susceptibility of HIV-associated neurocognitive disorder (HAND).

104 brovascular disease (CVD) and HIV-associated neurocognitive disorder (HAND).

105 d potentially ongoing role in HIV-associated neurocognitive disorder (HAND).

106 tes with cognitive decline in HIV-associated neurocognitive disorder (HAND).

107 erapy (ART), chronic forms of HIV-associated neurocognitive disorders (HAND) affect an estimated 50%

108 by the rising incidence of HIV-1-associated neurocognitive disorders (HAND) among infected individua

109 onic complications, including HIV-associated neurocognitive disorders (HAND) and eye diseases.

110 rent non-infectious models of HIV-associated neurocognitive disorders (HAND) and reveals a precise co

111 clades differentially induce HIV-associated neurocognitive disorders (HAND) and substance abuse is k

112 HIV-associated neurocognitive disorders (HAND) are commonly linked with

113 uman immunodeficiency virus (HIV)-associated neurocognitive disorders (HAND) are not routinely assess

114 HIV-associated neurocognitive disorders (HAND) are prevalent despite co

115 at plays an important role in HIV-associated neurocognitive disorders (HAND) by disrupting neurotrans

116 lia play a pathogenic role in HIV-associated neurocognitive disorders (HAND) by instigating primary d

117 uman immunodeficiency virus (HIV)-associated neurocognitive disorders (HAND) can show variable clinic

118 he most challenging issues in HIV-associated neurocognitive disorders (HAND) caused by HIV-1 virotoxi

119 uman immunodeficiency virus (HIV)-associated neurocognitive disorders (HAND) criteria are frequently

120 HIV-associated neurocognitive disorders (HAND) have been suggested as p

121 rvous system (CNS) and causes HIV-associated neurocognitive disorders (HAND) in about half of the pop

122 discusses current concepts of HIV-associated neurocognitive disorders (HAND) in the era of antiretrov

123 HIV-associated neurocognitive disorders (HAND) in the era of combinatio

124 uman immunodeficiency virus (HIV)-associated neurocognitive disorders (HAND) is a significant source

125 HIV-associated neurocognitive disorders (HAND) is a term describing a c

126 HIV-associated neurocognitive disorders (HAND) is characterized by deve

127 however, the prevalence of HIV-1-associated neurocognitive disorders (HAND) is still increasing.

128 ecreased, but milder forms of HIV-associated neurocognitive disorders (HAND) persist along with motor

129 ecreased, but milder forms of HIV-associated neurocognitive disorders (HAND) persist along with motor

130 uman immunodeficiency virus (HIV)-associated neurocognitive disorders (HAND) reflect the spectrum of

131 IV infection is now possible, HIV-associated neurocognitive disorders (HAND) remain intractable.

132 , progression, and outlook of HIV-associated neurocognitive disorders (HAND) remain unclear.

133 antibody profiles track with HIV-associated neurocognitive disorders (HAND) remains unclear.

134 the pathophysiology of these HIV-associated neurocognitive disorders (HAND) remains unresolved.

135 HIV-associated neurocognitive disorders (HAND) represent a spectrum dis

136 vation better correlates with HIV-associated neurocognitive disorders (HAND) than productive HIV-1 in

137 uman immunodeficiency virus (HIV)-associated neurocognitive disorders (HAND) that result from HIV inf

138 The continued prevalence of HIV-associated neurocognitive disorders (HAND) underscores the need for

139 generative diseases such as HIV-1-associated neurocognitive disorders (HAND), Alzheimer's disease (AD

140 he neurodegenerative syndrome HIV-associated neurocognitive disorders (HAND), for which there is no s

141 uman immunodeficiency virus (HIV) associated neurocognitive disorders (HAND), including memory dysfun

142 ted individuals still develop HIV-Associated Neurocognitive Disorders (HAND), indicating that host in

143 process, now referred to as HIV-1-associated neurocognitive disorders (HAND), provides a range of mol

144 of Parkinson's disease and HIV-1 associated neurocognitive disorders (HAND), requiring an inhibitor

145 The 2007 criteria for HIV-associated neurocognitive disorders (HAND), sometimes called the Fr

146 1 in the brain often leads to HIV associated neurocognitive disorders (HAND), such as encephalitis an

147 ate abusers and patients with HIV-associated neurocognitive disorders (HAND), which is typically exac

148 ogical complications, such as HIV-associated neurocognitive disorders (HAND), which result in cogniti

149 iduals frequently suffer from HIV-associated neurocognitive disorders (HAND), with about 30% of AIDS

150 he most prevalent features of HIV-associated neurocognitive disorders (HAND), yet their origins are u

151 immunodeficiency virus-1 (HIV-1)-associated neurocognitive disorders (HAND).

152 ction, who may be at risk for HIV-Associated Neurocognitive Disorders (HAND).

153 ies continue, which include HIV-1-associated neurocognitive disorders (HAND).

154 ribute to the pathogenesis of HIV-associated neurocognitive disorders (HAND).

155 increased risk of developing HIV-associated neurocognitive disorders (HAND).

156 us type 1 (HIV-1) suffer from HIV-associated neurocognitive disorders (HAND).

157 nfection of the brain induces HIV-associated neurocognitive disorders (HAND).

158 cript levels in patients with HIV-associated neurocognitive disorders (HAND).

159 ological disorders, including HIV-associated neurocognitive disorders (HAND).

160 ation of the progression of HIV-1 associated neurocognitive disorders (HAND).

161 y disease, may play a role in HIV-associated neurocognitive disorders (HAND).

162 d individuals still develop HIV-1 associated neurocognitive disorders (HAND).

163 stress and the occurrence of HIV-associated neurocognitive disorders (HAND).

164 licated in the development of HIV-associated neurocognitive disorders (HAND).

165 ed or with various degrees of HIV-associated neurocognitive disorders (HAND).

166 f HIV-infected people exhibit HIV-associated neurocognitive disorders (HAND).

167 immunodeficiency virus 1 (HIV-1)-associated neurocognitive disorders (HAND).

168 the main underlying causes of HIV-associated neurocognitive disorders (HAND).

169 HIV-positive individuals with HIV-associated neurocognitive disorders (HAND).

170 tes toward the development of HIV-associated neurocognitive disorders (HAND).

171 restorative therapeutic for HIV-1 associated neurocognitive disorders (HAND); its therapeutic utility

172 panied with the prevalence of HIV-associated neurocognitive disorders (HANDs) and risk of comorbiditi

173 HIV-associated neurocognitive disorders (HANDs) are a frequent outcome

174 uman immunodeficiency virus (HIV)-associated neurocognitive disorders (HANDs) remain among the most c

175 owever, the role of nAChRs in HIV-associated neurocognitive disorder has not been investigated.

176 The neuropathology underlying HIV-associated neurocognitive disorders has not been well characterized

177 HIV-associated neurocognitive disorders, however, continue to be a majo

178 hanges linked with HIV infection and related neurocognitive disorders; however, group-level compariso

179 ber variants (CNVs) are associated with many neurocognitive disorders; however, these events are typi

180 nd concurrent validity of DSM-5 criteria for neurocognitive disorder in Down syndrome.

181 escribe the manifestations of HIV-associated neurocognitive disorder in the era of effective HIV ther

182 a neuroinflammatory response and subsequent neurocognitive disorders in adulthood.

183 in socioeconomic inequalities in relation to neurocognitive disorders in later life and the potential

184 r life could contribute to the prevalence of neurocognitive disorders in later life.

185 biomarkers to diagnose people with suspected neurocognitive disorders in memory clinics.

186 ationship between socioeconomic position and neurocognitive disorders in older adults.

187 pathological presentation of HIV-associated neurocognitive disorders in the post-ARV era.

188 ing or brain DHA are associated with various neurocognitive disorders including Alzheimer's disease (

189 tance use and psychotic disorders, seizures, neurocognitive disorders (including Alzheimer's disease

190 Disease-modifying treatments for major neurocognitive disorders, including Alzheimer's disease,

191 s in impulse control are observed in several neurocognitive disorders, including attention deficit hy

192 ular diseases, cerebrovascular diseases, and neurocognitive disorders, including current knowledge on

193 f synaptic connections is a hallmark of many neurocognitive disorders, including HAND.

194 f GLP-1RAs for the care of people with major neurocognitive disorders, including their individual bra

195 ular diseases, cerebrovascular diseases, and neurocognitive disorders, including vascular cognitive i

196 munodeficiency Virus type-1 (HIV)-associated neurocognitive disorder is characterized by recruitment

197 The number of people with neurocognitive disorder is increasing, and the majority

198 f the diagnostic criteria for HIV-associated neurocognitive disorders is a cornerstone of the propose

199 Dementia (also known as major neurocognitive disorder) is defined by a significant dec

200 and prevention strategies for HIV-associated neurocognitive disorders likely need to be tailored base

201 atest source of years lived with disability: neurocognitive disorders, major depression, schizophreni

202 lth) measured in 2008/09 was associated with neurocognitive disorders measured in 2018/19.

203 her sequelae that include nervous system and neurocognitive disorders, mental health disorders, metab

204 ly being used in clinical practice for minor neurocognitive disorder (MND) as well as HAD, despite un

205 ated with a higher risk of investigation for neurocognitive disorders (n = 25 668 children; adjusted

206 ow certainty) as well as proven or suspected neurocognitive disorders (n = 529 205 children; aHR, 1.1

207 ke, major adverse cardiac events (MACE), and neurocognitive disorders (NCD).

208 t for preventing and treating HIV-associated neurocognitive disorder; nevertheless, clear cerebrospin

209 eted for regular screening for HIV-associate neurocognitive disorder, particularly with tests referab

210 uman immunodeficiency virus (HIV)-associated neurocognitive disorders persist despite suppressive ant

211 rgery and its contribution to peri-operative neurocognitive disorders (PND) is not well understood.

212 Perioperative neurocognitive disorders (PNDs) are characterized by con

213 HIV-associated neurocognitive disorders prevail in 20-50 percent of inf

214 eclinical Alzheimer's disease (AD) and other neurocognitive disorders remain an unmet need.

215 Neurocognitive disorders remain common among human immun

216 HIV-associated neurocognitive disorders remain prevalent among HIV type

217 itive impairments, that is, HIV-1-associated neurocognitive disorders remain prevalent potentially du

218 ly relevant HIV-associated dementia and mild neurocognitive disorder sensitivity was 100% and specifi

219 -established as valuable tools for detecting neurocognitive disorders such as mild cognitive impairme

220 t cognitive deficits in neuropsychiatric and neurocognitive disorders that are associated with altera

221 t cognitive deficits in neuropsychiatric and neurocognitive disorders that are associated with altera

222 e findings may have a significant impact for neurocognitive disorders that inhibit memory consolidati

223 iatric Association criteria for psychosis in neurocognitive disorders, the Alzheimer's Association In

224 , ICD-10 and DSM-5 criteria for dementia (or neurocognitive disorder) to each case.

225 of Ageing (ELSA, n = 4,815), we ascertained neurocognitive disorders using a recognised consensus cr

226 uman immunodeficiency virus (HIV)-associated neurocognitive disorders, we examined persons with acqui

227 uman immunodeficiency virus (HIV)-associated neurocognitive disorders, we quantified HIV type 1 (HIV-

228 of 109 older adults without a diagnosis of a neurocognitive disorder were enrolled in the study; 44 w

229 uding Alzheimer's disease and HIV-associated neurocognitive disorders where APP misprocessing to amyl

230 nces of cardiometabolic, musculoskeletal and neurocognitive disorders, whereas early puberty is assoc

231 good inter-rater reliability apart from mild neurocognitive disorder which was moderate (k = 0.494).

232 Our study identifies a RAB1A-related neurocognitive disorder with speech and motor delay, dem

233 g users have an increased risk of developing neurocognitive disorders with increased progression to d

234 brain health issues associated with HIV (eg, neurocognitive disorders), with specific considerations

235 ought to play a causal role in perioperative neurocognitive disorders, yet the role of these lipids i